NCT04134598View on ClinicalTrials.gov

ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

926

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions
Breast Cancer
Interventions
RADIATION

Breast irradiation (RT)

Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.

DRUG

Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen

Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).

Trial Locations (1)

50141

Azienda Ospedaliero-Universitaria Careggi, Florence University, Florence

All Listed Sponsors
collaborator

University of Florence

OTHER

lead

Azienda Ospedaliero-Universitaria Careggi

OTHER